References
- Goldberg JF , CitromeL . Latest therapies for bipolar disorder. Looking beyond lithium . Postgrad. Med.117 ( 2 ), 25–36 ( 2005 ).
- Rogawski MA , LöscherW . The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions . Nat. Med.10 ( 7 ), 685 – 692 ( 2004 ).
- Stewart JD , HorvathR , BaruffiniEet al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity . Hepatology52 ( 5 ), 1791 – 1796 ( 2010 ).
- Bots M , VerbruggeI , MartinBPet al. Differentiation therapy for the treatment of t (8; 21) acute myeloid leukemia using histone deacetylase inhibitors . Blood123 ( 9 ), 1341 – 1352 ( 2014 ).
- Poggi A , CatellaniS , GarutiA , PierriI , GobbiM , ZocchiMR . Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate . Leukemia23 ( 4 ), 641 – 648 ( 2009 ).
- Issa JP , Garcia-ManeroG , HuangXet al. Results of Phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia . Cancer121 ( 4 ), 556 – 561 ( 2015 ).
- Torgersen ML , EngedalN , B⊘eSO , HoklandP , SimonsenA . Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t (8; 21) AML cells . Blood122 ( 14 ), 2467 – 2476 ( 2013 ).
- Gugler R , von UnruhGE . Clinical pharmacokinetics of valproic acid . Clin. Pharmacokinet.5 ( 1 ), 67 – 83 ( 1980 ).
- Klotz U , RappT , MüllerWA . Disposition of valproic acid in patients with liver disease . Eur. J. Clin. Pharmacol.13 ( 1 ), 55 – 60 ( 1978 ).
- Bruni J , AlbrightPS . The clinical pharmacology of antiepileptic drugs . Clin. Neuropharmacol.7 ( 1 ), 1 – 34 ( 1984 ).
- Argikar UA , RemmelRP . Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10 . Drug Metab. Dispos.37 ( 1 ), 229 – 236 ( 2009 ).
- Guo Y , HuC , HeX , QiuF , ZhaoL . Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy . Drug Metab. Pharmacokinet.27 ( 5 ), 536 – 542 ( 2012 ).
- Patsalos PN , PeruccaE . Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs . Lancet Neurol.2 ( 8 ), 473 – 481 ( 2003 ).
- Tanaka E . Clinically significant pharmacokinetic drug interactions between antiepileptic drugs . J. Clin. Pharm. Ther.24 ( 2 ), 87 – 92 ( 1999 ).
- Inoue K , SuzukiE , YazawaRet al. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients . Ther. Drug Monit.36 ( 3 ), 406 – 409 ( 2014 ).
- Parmeggiani A , RivaR , PosarA , RossiPG . Possible interaction between acyclovir and antiepileptic treatment . Ther. Drug Monit.17 ( 3 ), 312 – 315 ( 1995 ).
- Sun YX , ZhuoWY , LinHet al. The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients . Epilepsy Res.114 , 78 – 80 ( 2015 ).
- Dutta S , FaughtE , LimdiNA . Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy . J. Clin. Pharm. Ther.32 ( 4 ), 365 – 371 ( 2007 ).
- Kayser FH , MorenzoniG , SträssleA , HadornK . Activity of meropenem, against Gram-positive bacteria . J. Antimicrob. Chemother.24 ( Suppl. A ), 101 – 112 ( 1989 ).
- Sanders CC , SandersWEJr , ThomsonKS , IaconisJP . Meropenem: activity against resistant Gram-negative bacteria and interactions with beta-lactamases . J. Antimicrob. Chemother.24 ( Suppl. A ), 187 – 196 ( 1989 ).
- Nord CE , LindmarkA , PerssonI . Susceptibility of anaerobic bacteria to meropenem . J. Antimicrob. Chemother.24 ( Suppl. A ), 113 – 117 ( 1989 ).
- Nagai K , ShimizuT , TogoAet al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron . J. Antimicrob. Chemother.39 ( 2 ), 295 – 296 ( 1997 ).
- Vélez Díaz-Pallarés M , Delgado SilveiraE , Alvarez DíazAM , Pérez Menéndez-CondeC , Vicente OliverosN , Bermejo VicedoT . Analysis of the valproic acid-meropenem interaction in hospitalised patients . Neurologia27 ( 1 ), 34 – 38 ( 2012 ).
- Fudio S , CarcasA , PiñanaE , OrtegaR . Epileptic seizures caused by low valproic acid levels from an interaction with meropenem . J. Clin. Pharm. Ther.31 ( 4 ), 393 – 396 ( 2006 ).
- Mori H , TakahashiK , MizutaniT . Interaction between valproic acid and carbapenem antibiotics . Drug Metab. Rev.39 ( 4 ), 647 – 657 ( 2007 ).
- Nacarkucuk E , SaglamH , OkanM . Meropenem decreases serum level of valproic acid . Pediatr. Neurol.31 ( 3 ), 232 – 234 ( 2004 ).
- Spriet I , MeerssemanW , De TroyE , WilmerA , CasteelsM , WillemsL . Meropenem–valproic acid interaction in patients with cefepime-associated status epilepticus . Am. J. Health Syst. Pharm.64 ( 1 ), 54 – 58 ( 2007 ).
- Suzuki E , YamamuraN , OguraYet al. Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics . Drug Metab. Dispos.38 ( 9 ), 1538 – 1544 ( 2010 ).
- Suzuki E , NakaiD , YamamuraN , KobayashiN , OkazakiO , IzumiT . Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid . Xenobiotica41 ( 11 ), 958 – 963 ( 2011 ).
- Suzuki E , NakaiD , IkenagaHet al. In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs . Xenobiotica46 ( 2 ), 126 – 131 ( 2015 ).
- Chinese Clinical Trial Registry . http://www.chictr.org.cn .
- 1000 Genomes . www.1000genomes.org/ .
- Shi YY , HeL . SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci . Cell Res.15 ( 2 ), 97 – 98 ( 2005 ).
- Omoda K , MurakamiT , YumotoRet al. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human . J. Pharm. Sci.94 ( 8 ), 1685 – 1693 ( 2005 ).
- Kojima S , NadaiM , KitaichiK , WangL , NabeshimaT , HasegawaT . Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats . Antimicrob. Agents Chemother.42 ( 12 ), 3136 – 3140 ( 1998 ).
- Yokogawa K , IwashitaS , KubotaAet al. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits . Pharm. Res.18 ( 9 ), 1320 – 1326 ( 2001 ).
- Nakajima Y , MizobuchiM , NakamuraMet al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats . Drug Metab. Dispos.32 ( 12 ), 1383 – 1391 ( 2004 ).
- Yamamura N , Imura-MiyoshiK , NaganumaH . Panipenum, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats . Drug Metab. Dispos.28 ( 12 ), 1484 – 1486 ( 2000 ).
- Guo Y , HuC , HeX . Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy . Drug Metab. Pharmacokinet.27 ( 5 ), 536 – 542 ( 2012 ).
- Chu XM , ZhangLF , WangGJet al. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients . Eur. J. Clin. Pharmacol.68 ( 10 ), 1395 – 1401 ( 2012 ).
- Inoue K , SuzukiE , YazawaRet al. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients . Ther. Drug Monit.36 ( 3 ), 406 – 409 ( 2014 ).
- Tan L , YuJT , SunYPet al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients . Clin. Neurol. Neurosurg.112 ( 4 ), 320 – 323 ( 2010 ).